セファマンドール
- 関
- cefamandole sodium
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2015/06/04 17:30:15」(JST)
[Wiki en表示]
Cefamandole
|
Systematic (IUPAC) name |
(6R,7R)-7-{[(2R)-2-hydroxy-2-phenylacetyl]amino}-
3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-
5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
Clinical data |
Trade names |
former Mandol |
AHFS/Drugs.com |
Micromedex Detailed Consumer Information |
MedlinePlus |
a601206 |
Pregnancy
category
|
|
Legal status
|
- UK: Prescription-only (POM)
- Discontinued (US)
|
Routes of
administration
|
Intramuscular, intravenous |
Pharmacokinetic data |
Protein binding |
75% |
Half-life |
48 minutes |
Excretion |
Mostly renal, as unchanged drug |
Identifiers |
CAS Registry Number
|
34444-01-4 Y 42540-40-9 |
ATC code
|
J01DC03 |
PubChem |
CID 456255 |
DrugBank |
DB01326 Y |
ChemSpider |
401748 Y |
UNII |
5CKP8C2LLI Y |
KEGG |
D02344 Y |
ChEBI |
CHEBI:3480 Y |
ChEMBL |
CHEMBL1146 Y |
Chemical data |
Formula |
C18H18N6O5S2 |
Molecular mass
|
462.505 g/mol |
SMILES
- O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)[C@H](O)c3ccccc3)CSc4nnnn4C)C(=O)O
|
InChI
-
InChI=1S/C18H18N6O5S2/c1-23-18(20-21-22-23)31-8-10-7-30-16-11(15(27)24(16)12(10)17(28)29)19-14(26)13(25)9-5-3-2-4-6-9/h2-6,11,13,16,25H,7-8H2,1H3,(H,19,26)(H,28,29)/t11-,13-,16-/m1/s1 Y
Key:OLVCFLKTBJRLHI-AXAPSJFSSA-N Y
|
Y (what is this?) (verify) |
Cefamandole (INN, also known as cephamandole) is a second-generation broad-spectrum cephalosporin antibiotic. The clinically used form of cefamandole is the formate ester cefamandole nafate, a prodrug which is administered parenterally. Cefamandole is no longer available in the United States.
The chemical structure of cefamandole, like that of several other cephalosporins, contains an N-methylthiotetrazole (NMTT or 1-MTT) side chain. As the antibiotic is broken down in the body, it releases free NMTT, which can cause hypoprothrombinemia (likely due to inhibition of the enzyme vitamin K epoxide reductase)(vitamin K supplement is recommended during therapy) and a reaction with ethanol similar to that produced by disulfiram (Antabuse), due to inhibition of aldehyde dehydrogenase.
Cefamandole has a broad spectrum of activity and can be used to treat bacterial infections of the skin, bones and joints, urinary tract, and lower respiratory tract. The following represents cefamandole MIC susceptibility data for a few medically significant microorganisms.
- Escherichia coli: 0.12 - 400 μg/ml
- Haemophilus influenzae: 0.06 - >16 μg/ml
- Staphylococcus aureus: 0.1 - 12.5 μg/ml
[1]
CO2 is generated during the normal constitution of cefamandole and ceftazidim, resulting in an explosive-like reaction in syringes.[2]
References
- ^ http://www.toku-e.com/Assets/MIC/Cefamandole%20sodium%20salt.pdf
- ^ Stork CM (2006). "Antibiotics, antifungals, and antivirals". In Nelson LH, Flomenbaum N, Goldfrank LR, Hoffman RL, Howland MD, Lewin NA (eds.). Goldfrank's toxicologic emergencies. New York: McGraw-Hill. p. 847. ISBN 0-07-143763-0. Retrieved 2009-07-03.
Antibacterials: cell envelope antibiotics (J01C-J01D)
|
|
Intracellular |
- inhibit peptidoglycan subunit synthesis and transport: NAM synthesis inhibition (Fosfomycin)
- DADAL/AR inhibitors (Cycloserine)
- bactoprenol inhibitors (Bacitracin)
|
|
Glycopeptide |
- inhibit PG chain elongation: Vancomycin# (Oritavancin
- Telavancin)
- Teicoplanin (Dalbavancin)
- Ramoplanin
|
|
β-lactams/
(inhibit PBP
cross-links) |
|
|
Other |
- polymyxins/detergent
- depolarizing
- hydrolyze NAM-NAG
- Gramicidin
- Isoniazid
- Teixobactin
|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
Index of bacterial disease
|
|
Description |
|
|
Disease |
- Gram-positive firmicutes
- Gram-positive actinobacteria
- Gram-negative proteobacteria
- Gram-negative non-proteobacteria
- Cholera
- Tuberculosis
|
|
Treatment |
- Antibiotics
- cell wall
- nucleic acid
- mycobacteria
- protein synthesis
- other
- Antibodies
- Vaccines
|
|
|
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. セフェム系 cephalosporins
- 2. 持続的腎代替療法中の薬物除去 drug removal during continuous renal replacement therapy
- 3. 薬疹 drug eruptions
- 4. レジオネラ感染の臨床症候および診断 clinical manifestations and diagnosis of legionella infection
- 5. 成人における手術部位感染症の疫学 epidemiology of surgical site infection in adults
English Journal
- Prospective survey of acute osteoarticular infections in a French paediatric orthopedic surgery unit.
- Ferroni A, Al Khoury H, Dana C, Quesne G, Berche P, Glorion C, Péjin Z.SourceHôpital Necker Enfants-Malades, Laboratoire de Bactériologie Hôpital Necker-Enfants Malades, Unité de Chirurgie Orthopédique Pédiatrique, Paris, France.
- Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.Clin Microbiol Infect.2013 Sep;19(9):822-8. doi: 10.1111/clm.12031.
- The epidemiology of acute paediatric osteoarticular infections (OAI) has recently evolved, mainly due to the improvement of microbiological diagnosis. We conducted a prospective study to analyse the recent epidemiology and the clinical evolution of paediatric OAI in order to validate the adequacy of
- PMID 23957786
- Validation of the cephalosporin intradermal skin test for predicting immediate hypersensitivity: a prospective study with drug challenge.
- Yoon SY, Park SY, Kim S, Lee T, Lee YS, Kwon HS, Cho YS, Moon HB, Kim TB.SourceDivision of Allergy and Clinical Immunology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Allergy.Allergy.2013 Jul;68(7):938-44. doi: 10.1111/all.12182. Epub 2013 Jun 10.
- BACKGROUND: Cephalosporin is a major offending agent in terms of drug hypersensitivity along with penicillin. Cephalosporin intradermal skin tests (IDTs) have been widely used; however, their validity for predicting immediate hypersensitivity has not been studied. This study aimed to determine the p
- PMID 23751142
- Hemophagocytic syndrome as uncommon presentation of disseminated toxoplasmosis in an immunocompetent adult from Chinese Kunming.
- Yang Y, Zuo W, Hu J, Esch GW, Zuo Y.SourceKey Laboratory for Animal Genetic Diversity and Evolution of High Education in Yunnan Province, Yunnan University, Kunming, China. 12011000936@mail.ynu.edu.cn
- The American journal of tropical medicine and hygiene.Am J Trop Med Hyg.2013 Jun;88(6):1209-11. doi: 10.4269/ajtmh.12-0556. Epub 2013 Mar 18.
- Hemophagocytic syndrome is a rare disease that is often fatal, despite treatment. An immunocompetent patient was presented with fever, hepatosplenomegaly, cytopenias, hypertriglyceridemia, hypofibrinogenemia, and hyperferritinemia, which conformed to a hemophagocytic syndrome diagnosis. Despite broa
- PMID 23509123
Japanese Journal
- Effects of antineoplastics, antibiotics and antidiabetics on acetaldehyde metabolism after alcohol ingestion.
- メチシリン感受性および耐性黄色ブドウ球菌へのセフメタゾールとセフォチァム,セファマンドールまたはセフォペラゾンの併用による相乗的in vitro抗菌力増強作用 : II. 接種菌量の影響
- メチシリン感受性および耐性黄色ブドウ球菌へのセフメタゾールとセファゾリン,セフォチァム,セファマンドールまたはセフォペラゾンの併用による相乗的 in vitro抗菌力増強作用 : I.NaC1の影響
Related Links
- cefamandole /cef·a·man·dole/ (-man´dōl) a semisynthetic second-generation cephalosporin antibiotic; used primarily as c. nafate, the sodium salt of the cefamandole formyl ester. cefamandole [sef″ah-man´dōl] a semisynthetic broad ...
- Cefamandole - Get up-to-date information on Cefamandole side effects, uses, dosage, overdose, pregnancy, alcohol and more. Learn more about Cefamandole ... Cefamandole is used in the treatment of: Bone Diseases, Infectious
★リンクテーブル★
[★]
- 英
- cefamandole、cefamandole sodium
- 関
- セファマンドールナトリウム
[★]
- 関
- cefamandole